King divests Prefest
Executive Summary
Barr acquires King's hormone replacement therapy Prefest for approximately $15 mil. The deal is part of King's strategy to divest "many, if not all" of its women's health products, King said Nov. 22. Barr and King are involved in pending litigation over patents related to Prefest (estradiol/norgestimate); the case will be voluntarily dismissed after the product acquisition. King has plans to merge with Mylan (1"The Pink Sheet" Nov. 1, 2004, p. 21)...
Barr acquires King's hormone replacement therapy Prefest for approximately $15 mil. The deal is part of King's strategy to divest "many, if not all" of its women's health products, King said Nov. 22. Barr and King are involved in pending litigation over patents related to Prefest (estradiol/norgestimate); the case will be voluntarily dismissed after the product acquisition. King has plans to merge with Mylan (1 , p. 21).... |